Cancer Treatment Reviews
Volume 36, Issue 2 , Pages 164-176 , April 2010

An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome

  • Tariq I. Mughal

      Affiliations

    • Department of Haematology, Guy’s & St Thomas’s NHS Hospital, London SE1 9RT, UK
    • Corresponding Author InformationCorresponding author. Tel.: +1 901 497 1185.
    • ,
  • A. Ahsan Ejaz

      Affiliations

    • Division of Nephrology, Hypertension and Transplantation, University of Florida, P.O. Box 100224, Gainesville, FL 32610, USA
    • Tel.: +1 352 265 0139; fax: +1 352 392 3581.
    • ,
  • John R. Foringer

      Affiliations

    • The Division of Renal Diseases and Hypertension, Section of Critical Care Nephrology, The University of Texas, Medical School at Houston, M.D. Anderson Cancer Center, Houston, TX 77030, USA
    • Tel.: +1 713 500 6868; fax: +1 713 500 6882.
    • ,
  • Bertrand Coiffier

      Affiliations

    • Department of Hematology, Hospices Civils de Lyon, Lyon, France
    • Tel.: +33 04 78 86 11 93; fax: +33 04 78 86 65 68.

Received 8 September 2009 ,Revised 29 October 2009 ,Accepted 3 November 2009.

References 

  1. Bessmertny O, Robitaille LM, Cairo MS. Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome. Curr Pharm Des. 2005;11:4177–4185
  2. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Brit J Haematol. 2004;127:3–11
  3. Hochberg J, Cairo MS. Tumor lysis syndrome: current perspective. Haematologica. 2008;93:9–13
  4. Locatelli F, Rossi F. Incidence and pathogenesis of tumor lysis syndrome. Contrib Nephrol. 2005;147:61–68
  5. Rampello E, Fricia T, Malaguarnera M. The management of tumor lysis syndrome. Nat Clin Pract Oncol. 2006;3:438–447
  6. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26:2767–2778
  7. Chasty RC, Liu-Yin JA. Acute tumour lysis syndrome. Brit J Hosp Med. 1993;49:488–492
  8. Seidemann K, Meyer U, Jansen P, Yakisan E, Rieske K, Fuhrer M, et al. Impaired renal function and tumor lysis syndrome in pediatric patients with non-Hodgkin’s lymphoma and B-ALL: observations from the BFM-trials. Klin Padiatr. 1998;210:279–284
  9. Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin’s lymphoma. Am J Med. 1993;94:133–139
  10. Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood. 2007;109:399–404
  11. Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA, et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009; October 13 [Epub ahead of print].
  12. Annemans L, Moeremans K, Lamotte M, Garcia CJ, van den Berg H, Myint H, et al. Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin’s lymphoma in four European countries. Leukemia Lymphoma. 2003;44:77–83
  13. Kedar A, Grow W, Neiberger RE. Clinical versus laboratory tumor lysis syndrome in children with acute leukemia. Pediatr Hemat Oncol. 1995;12:129–134
  14. Montesinos P, Lorenzo I, Martin G, Sanz J, Perez-Sirvent ML, Martinez D, et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica. 2008;93:67–74
  15. Wossmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A. Incidence of tumor lysis syndrome in children with advanced stage Burkitt’s lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol. 2003;82:160–165
  16. Stapleton FB, Strother DR, Roy S, Wyatt RJ, McKay CP, Murphy SB. Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma. Pediatrics. 1988;82:863–869
  17. Baeksgaard L, Sorensen JB. Acute tumor lysis syndrome in solid tumors – a case report and review of the literature. Cancer Chemother Pharmacol. 2003;51:187–192
  18. Gemici C. Tumour lysis syndrome in solid tumours. Clin Oncol (R Coll Radiol). 2006;18:773–780
  19. Mott FE, Esana A, Chakmakjian C, Herrington JD. Tumor lysis syndrome in solid tumors. Support Cancer Ther. 2005;2:188–191
  20. Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0. National Cancer Institute. Published April 30, 1999. <http://ctep.cancer.gov/protocol Development/electronic_applications/ctc.htm ctc_20> [accessed 5.10.08].
  21. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, version 3.0. National Cancer Institute. Published August 9, 2006. <http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf> [accessed 5.10.08].
  22. Ten Harkel AD, Kist-Van Holthe JE, Van WM, Van der Vorst MM. Alkalinization and the tumor lysis syndrome. Med Pediatr Oncol. 1998;31:27–28
  23. Conger JD, Falk SA. Intrarenal dynamics in the pathogenesis and prevention of acute urate nephropathy. J Clin Invest. 1977;59:786–793
  24. Band PR, Silverberg DS, Henderson JF, Ulan RA, Wensel RH, Banerjee TK, et al. Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N Engl J Med. 1970;283:354–357
  25. Halperin ML, Cheema DS, Kamel KS. Physiology of acid-base balance: links with kidney stone prevention. Semin Nephrol. 2006;26:441–446
  26. LaRosa C, McMullen L, Bakdash S, Ellis D, Krishnamurti L, Wu HY, et al. Acute renal failure from xanthine nephropathy during management of acute leukemia. Pediatr Nephrol. 2007;22:132–135
  27. Potter JL, Silvidi AA. Xanthine lithiasis, nephrocalcinosis, and renal failure in a leukemia patient treated with allopurinol. Clin Chem. 1987;33:2314–2316
  28. Veenstra J, Krediet RT, Somers R, Arisz L. Tumour lysis syndrome and acute renal failure in Burkitt’s lymphoma: description of 2 cases and a review of the literature on prevention and management. Neth J Med. 1994;45:211–216
  29. Tosi P, Barosi G, Lazzaro C, Liso V, Marchetti M, Morra E, et al. Consensus conference on the management of tumor lysis syndrome. Haematologica. 2008;93:1877–1885
  30. Mehta RL, Pascual MT, Soroko S, Chertow GM. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA. 2002;288:2547–2553
  31. Jones DP, Mahmoud H, Chesney RW. Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol. 1995;9:206–212
  32. Karajala V, Mansour W, Kellum JA. Diuretics in acute kidney injury. Minerva Anestesiol. 2009;75:251–257
  33. Redfors B, Sward K, Sellgren J, Ricksten SE. Effects of mannitol alone and mannitol plus furosemide on renal oxygen consumption, blood flow and glomerular filtration after cardiac surgery. Intensive Care Med. 2009;35:115–122
  34. Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001;97:2998–3003
  35. Aloprim® (allopurinol sodium) for injection [package insert]. Boca Raton, FL: Nabi; 2003.
  36. Zyloprim® (allopurinol) [package insert]. San Diego, CA: Prometheus Laboratories, Inc.; 2003.
  37. Elitek® (rasburicase) [package insert]. Bridgewater, NJ: sanofi-aventis; 2008.
  38. DeConti RC, Calabresi P. Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease. N Engl J Med. 1966;274:481–486
  39. Kann HE, Wells JH, Gallelli JF, Schein PS, Cooney DA, Smith ER, et al. The development and use of an intravenous preparation of allopurinol. Am J Med Sci. 1968;256:53–63
  40. Krakoff IH, Meyer RL. Prevention of hyperuricemia in leukemia and lymphoma: use of alopurinol, a xanthine oxidase inhibitor. JAMA. 1965;193:1–6
  41. Krakoff IH, Balis ME. Allopurinol in the prevention of hyperuricaemia secondary to the treatment of neoplastic diseases with alkylating agents, adrenal steroids, and radiation therapy. Ann Rheum Dis. 1966;25:651–654
  42. Smalley RV, Guaspari A, Haase-Statz S, Anderson SA, Cederberg D, Hohneker JA. Allopurinol: intravenous use for prevention and treatment of hyperuricemia. J Clin Oncol. 2000;18:1758–1763
  43. Yeldandi AV, Yeldandi V, Kumar S, Murthy CV, Wang XD, Alvares K, et al. Molecular evolution of the urate oxidase-encoding gene in hominoid primates: nonsense mutations. Gene. 1991;109:281–284
  44. Yeldandi AV, Yeldandi V, Kumar S, Murthy CV, Wang XD, Alvares K, et al. Molecular evolution of the urate oxidase-encoding gene in hominoid primates: nonsense mutations. Gene. 1991;109:281–284
  45. Pui CH, Relling MV, Lascombes F, Harrison PL, Struxiano A, Mondesir JM, et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia. 1997;11:1813–1816
  46. Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol. 2001;19:697–704
  47. Bosly A, Sonet A, Pinkerton CR, McCowage G, Bron D, Sanz MA, et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer. 2003;98:1048–1054
  48. Coiffier B, Mounier N, Bologna S, Ferme C, Tilly H, Sonet A, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin’s lymphoma: results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol. 2003;21:4402–4406
  49. Cortes J, Seiter S, Maziarz RT, et al. Superiority of rasburicase versus allopurinol on serum uric acid control in adult patients with hematological malignancies at risk of developing tumor lysis syndrome: results of a randomized comparative phase III study [abstract 919]. In: Presented at: 50th ASH Annual Meeting and Exposition; December 6–9, 2008; San Francisco, CA. <http://ash.confex.com/ash/2008/webprogram/Paper1748.html> [accessed 05.10.08].
  50. Jeha S, Kantarjian H, Irwin D, Shen V, Shenoy S, Blaney S, et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia. 2005;19:34–38
  51. Renyi I, Bardi E, Udvardi E, Kovacs G, Bartyik K, Kajtar P, et al. Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin’s lymphoma. Pathol Oncol Res. 2007;13:57–62
  52. Shin HY, Kang HJ, Park ES, Choi HS, Ahn HS, Kim SY, et al. Recombinant urate oxidase (rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: results of a compassionate prospective multicenter study in Korea. Pediatr Blood Cancer. 2006;46:439–445
  53. Wang LY, Shih LY, Chang H, Jou ST, Lin KH, Yeh TC, et al. Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies. Acta Haematol. 2006;115:35–38
  54. Children’s Oncology Group. A pilot study to determine the toxicity of the addition of rituximab to the induction and consolidation phases and the addition of rasburicase to the reduction phase in children with newly diagnosed advanced B-cell leukemia/lymphoma treated with LMB/FAB therapy [Study IDs: CDR0000271941, COG-ANHL01P1; ClinicalTrials.gov Identifier: NCT00057811]. ClinicalTrials.org. Published December 2, 2008. <http://clinicaltrials.gov/ct2/show/NCT00057811> [accessed 07.04.03].
  55. Johann Wolfgang Goethe University Hospitals. Randomised phase III trial of effectivity and safety of rasburicase compared with allopurinol for treatment of hyperuricemia in patients with acute lymphoblastic leukemia or high-grade NHL with high risk of tumor lysis syndrome (>15yrs) [Study ID: GMALL08; ClinicalTrials.gov Identifier: NCT00199043]. ClinicalTrials.org. Published December 2, 2008. <http://clinicaltrials.gov/ct2/show/NCT00199043> [accessed 12.09.05].
  56. M.D. Anderson Cancer Center. Phase 2 study of rasburicase administered by two different schedules (fixed dosing vs. as needed dosing) in patients at high risk or potential risk for tumor lysis syndrome [Study ID: 2006-0918; ClinicalTrials.gov Identifier: NCT00628628]. ClinicalTrials.org. Published December 2, 2008. <http://clinicaltrials.gov/ct2/show/NCT00628628>. [accessed 25.02.08].
  57. sanofi-aventis. A randomized, multicenter, open-label, comparison of rasburicase (Fasturtec) versus allopurinol for the prophylaxis and treatment of hyperuricemia in chinese patients with leukaemia or lymphoma [Study ID: RASBU_L_00351; ClinicalTrials.gov Identifier: NCT00607152]. ClinicalTrials.org. Published December 2, 2008. <http://clinicaltrials.gov/ct2/show/NCT00607152> [accessed 22.01.08].
  58. St. Jude Children’s Research Hospital (sanofi-aventis). A study of rasburicase treatment for chemotherapy of malignancy-induced hyperuricemia in patients with a history of asthma allergies [Study ID: RASALL; ClinicalTrials.gov Identifier: NCT00186940]. ClinicalTrials.org. Published December 2, 2008. <http://clinicaltrials.gov/ct2/show/NCT00186940> [accessed 12.09.05].
  59. European Medicines Agency. Fasturtec European Public Assessment Report, revision 11. Published April 27, 2009. <http://www.emea.europa.eu/humandocs/PDFs/EPAR/fasturtec/H-331-PI-en.pdf> [accessed 17.03.09].
  60. Hutcherson DA, Gammon DC, Bhatt MS, Faneuf M. Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. Pharmacotherapy. 2006;26:242–247
  61. Liu CY, Sims-McCallum RP, Schiffer CA. A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy. Leukemia Res. 2005;29:463–465
  62. McDonnell AM, Lenz KL, Frei-Lahr DA, Hayslip J, Hall PD. Single-dose rasburicase 6mg in the management of tumor lysis syndrome in adults. Pharmacotherapy. 2006;26:806–812
  63. Reeves DJ, Bestul DJ. Evaluation of a single fixed dose of rasburicase 7.5mg for the treatment of hyperuricemia in adults with cancer. Pharmacotherapy. 2008;28:685–690
  64. Trifilio S, Gordon L, Singhal S, Tallman M, Evens A, Rashid K, et al. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant. 2006;37:997–1001
  65. Chertow GM, Levy EM, Hammermeister KE, Grover F, Daley J. Independent association between acute renal failure and mortality following cardiac surgery. Am J Med. 1998;104:343–348
  66. Coca SG, Peixoto AJ, Garg AX, Krumholz HM, Parikh CR. The prognostic importance of a small acute decrement in kidney function in hospitalized patients: a systematic review and meta-analysis. Am J Kidney Dis. 2007;50:712–720
  67. Ponte B, Felipe C, Muriel A, Tenorio MT, Liano F. Long-term functional evolution after an acute kidney injury: a 10-year study. Nephrol Dial Transpl. 2008;23:3859–3866
  68. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute kidney injury network. Report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:R31
  69. Vaidya VS, Waikar SS, Ferguson MA, Collings FB, Sunderland K, Gioules C, et al. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin Transplant Sci. 2008;1:200–208
  70. Devarajan P. Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol. 2006;17:1503–1520
  71. Shimada M, Johnson RJ, May WS, Lingegowda V, Sood P, Nakagawa T, et al. A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome. Nephrol Dial Transplant. 2009;24:2960–2964
  72. Antineoplastic Agents. Drug Facts and Comparisons 4.0 [Web]. St. Louis, MO: Wolters Kluwer Health, Inc.; 2009.
  73. Skeel RT. Handbook of cancer chemotherapy. 7th ed.. Baltimore, MD: Lippincott; 2007;
  74. Hsu CY, Ordonez JD, Chertow GM, Fan D, McCulloch CE, Go AS. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int. 2008;74:101–107
  75. Ishani A, Xue JL, Himmelfarb J, Eggers PW, Kimmel PL, Molitoris BA, et al. Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol. 2009;20:223–228
  76. Iseki K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, Takishita S. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res. 2001;24:691–697
  77. Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004;44:642–650
  78. Rosolowsky ET, Ficociello LH, Maselli NJ, Niewczas MA, Binns AL, Roshan B, et al. High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol. 2008;3:706–713
  79. Tomita M, Mizuno S, Yamanaka H, Hosoda Y, Sakuma K, Matuoka Y, et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol. 2000;10:403–409
  80. Schiffl H. Renal recovery from acute tubular necrosis requiring renal replacement therapy : a prospective study in critically ill patients. Nephrol Dial Transplant. 2006;21:1248–1252
  81. Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, et al. Continuous renal replacement therapy: a worldwide practice survey: the beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators. Intens Care Med. 2007;33:1563–1570
  82. Cho KC, Himmelfarb J, Paganini E, Ikizler TA, Soroko SH, Mehta RL, et al. Survival by dialysis modality in critically ill patients with acute kidney injury. J Am Soc Nephrol. 2006;17:3132–3138
  83. Palevsky PM, Zhang JH, O’Connor TZ, Chertow GM, Crowley ST, Choudhury D, et al. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med. 2008;359:7–20
  84. Ratanarat R, Brendolan A, Volker G, Bonello M, Salvatori G, Andrikos E, et al. Phosphate kinetics during different dialysis modalities. Blood Purificat. 2005;23:83–90
  85. Michallet AS, Tartas S, Coiffier B. Optimizing management of tumor lysis syndrome in adults with hematologic malignancies. Support Cancer Ther. 2005;2:159–166
  86. Foringer JR, Norris C, Finkel KW. Potassium disorders. In: Molony DA, Craig JC, editors. Evidence-based nephrology. 1st ed. San Francisco, CA: Wiley-Blackwell; 2008. p. 635–6 [Table 56.3].

PII: S0305-7372(09)00162-5

doi: 10.1016/j.ctrv.2009.11.001

Cancer Treatment Reviews
Volume 36, Issue 2 , Pages 164-176 , April 2010

Article Tools

* Image Usage & Resolution